MiniMed Group, Inc.MMED recently announced that the MiniMed Flex system is now available to Medicare and Medicare Advantage beneficiaries in the United States. The system was commercially rolled out in the United States for commercially insured and private-pay patients in March. The expanded coverage broadens access to the company’s smallest and only app-controlled insulin pump, enabling more people living with diabetes to benefit from its automated insulin delivery technology. Powered by the SmartGuard algorithm, the MiniMed Flex system is designed to simplify diabetes management by automatically adjusting insulin delivery every five minutes.
Per management, Medicare coverage for MiniMed Flex reflects the company's commitment to making advanced diabetes technology available to a broader population. MMED believes diabetes management is a continuous challenge and that eligible beneficiaries, regardless of age, should have access to tools that seamlessly fit into everyday life while helping reduce the overall burden of care.
Likely Trend of MMED Stock Following the News
MMED stock has gained 3.1% since the announcement on Wednesday. Year to date, shares of the company have lost 9% compared with the industry’s 1.4% fall. However, the S&P 500 has risen 7.5% during the same timeframe.
Medicare coverage is likely to strengthen MMED’s long-term growth prospects by increasing the addressable market for the MiniMed Flex platform. Broader reimbursement should support higher adoption among eligible beneficiaries while reinforcing recurring revenue opportunities from the company’s diabetes management ecosystem. Leveraging the proven SmartGuard technology behind the MiniMed 780G system enhances the platform’s credibility and could improve customer confidence. The announcement positions MiniMed to further strengthen its presence in the automated insulin delivery market as it continues to expand sensor compatibility.
MMED currently has a market capitalization of $4.73 billion.
Image Source: Zacks Investment Research
More on the News
MiniMed Flex is approximately half the size of the company’s previous insulin pumps, while still accommodating up to 300 units of insulin. Its compact design, combined with smartphone-based control, allows users to manage therapy with greater discretion and convenience. The system incorporates the same SmartGuard algorithm used in the MiniMed 780G platform, automatically adjusting insulin delivery every five minutes throughout the day and night to help optimize glucose management.
The expanded Medicare availability is supported by encouraging real-world evidence presented at the 86th American Diabetes Association Scientific Sessions. Data showed that Medicare beneficiaries using the MiniMed 780G system achieved glucose control outcomes that exceeded the American Diabetes Association’s recommended glycemic targets, reinforcing the effectiveness of the SmartGuard technology now available through MiniMed Flex.
At present, the MiniMed Flex system is offered in the United States with Medtronics’ Simplera Sync sensor. The company also plans to introduce compatibility with Abbott Laboratories' Instinct sensor later this summer, providing users with additional sensor options while expanding the platform’s flexibility.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global insulin delivery devices market size was estimated at $19.3 billion in 2025 and is expected to reach $35.2 billion by 2033, expanding at a CAGR of 7.8% from 2026 to 2033.
Growth is largely attributed to the rising global prevalence of diabetes, which has heightened the demand for advanced and user-friendly solutions for diabetes management.
Other News
In June, MMED commercially launched the MiniMed 780G automated insulin delivery system integrated with Abbott Laboratories' Instinct sensor and the MiniMed Go system integrated with the Instinct Go sensor across Europe. The rollout expands the company's sensor portfolio in the region and provides people with diabetes with greater flexibility and choice in managing their condition.
West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
McKesson reported a fourth-quarter fiscal 2026 adjusted EPS of $11.69, which beat the Zacks Consensus Estimate by 1.1%. Revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%.
McKesson has an estimated long-term earnings growth rate of 13.7%. MCK’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.1%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Keep it Clean. Please avoid obscene, vulgar, lewd,
racist or sexually-oriented language. PLEASE TURN OFF YOUR CAPS LOCK. Don't Threaten. Threats of harming another
person will not be tolerated. Be Truthful. Don't knowingly lie about anyone
or anything. Be Nice. No racism, sexism or any sort of -ism
that is degrading to another person. Be Proactive. Use the 'Report' link on
each comment to let us know of abusive posts. Share with Us. We'd love to hear eyewitness
accounts, the history behind an article.
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.